Kymera Therpaeutics

1:45 PM - 2:00 PM, Monday, June 3,2019 ・ Theater 3
Kymera Therapeutics is a biotechnology company pioneering advances in the field of targeted protein degradation. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. We have successfully demonstrated preclinical activity of our small molecule degraders targeting IRAK4 in MYD88 (myeloid differentiation primary response 88)-mutant lymphoma. Unlike conventional approaches that only inhibit IRAK4 kinase activity, Kymera’s protein degraders eliminate both the kinase-dependent and -independent (scaffolding) functions resulting in superior and broader efficacy by blocking all MYD88 downstream signaling across a broad range of pathologies with potential utility in oncology and immunology. Behind IRAK4 we also have several other new degrader programs in development using our proprietary platform
Speaker
photo
CBO
Kymera Therpaeutics